Rodent malaria prophylaxis by transdermal delivery of primaquine

The efficacy of a new transdermal delivery system of primaquine in order to obtain causal prophylaxis against sporozoite-induced Plasmodium yoelii infection was evaluated. A single administration of a 1.0 cm2 transdermal delivery system containing 5.0 mg of primaquine was able to protect 100% of treated mice. This result suggests that the transdermal route may be a very interesting approach for malaria prophylaxis and should encourage further studies in order to determine the absolute bioavailability of the drug as well as its dose-effect relationship.